Proteomic and phosphoproteomic analyses of myectomy tissue reveals difference between sarcomeric and genotype-negative hypertrophic cardiomyopathy

Garmany, Ramin and Bos, J. Martijn and Dasari, Surendra and Johnson, Kenneth L. and Tester, David J. and Giudicessi, John R. and dos Remedios, Cristobal and Maleszewski, Joseph J. and Ommen, Steve R. and Dearani, Joseph A. and Ackerman, Michael J. (2023) Proteomic and phosphoproteomic analyses of myectomy tissue reveals difference between sarcomeric and genotype-negative hypertrophic cardiomyopathy. Scientific Reports, 13 (1). ISSN 2045-2322

Full text not available from this repository.
Link to published document: http://doi.org/10.1038/s41598-023-40795-1

Abstract

Hypertrophic cardiomyopathy (HCM) is a genetically heterogenous condition with about half of cases remaining genetically elusive or non-genetic in origin. HCM patients with a positive genetic test (HCM(Sarc)) present earlier and with more severe disease than those with a negative genetic test (HCM(Neg)). We hypothesized these differences may be due to and/or reflect proteomic and phosphoproteomic differences between the two groups. TMT-labeled mass spectrometry was performed on 15 HCM(Sarc), 8 HCM(Neg), and 7 control samples. There were 243 proteins differentially expressed and 257 proteins differentially phosphorylated between HCM(Sarc) and HCM(Neg). About 90% of pathways altered between genotypes were in disease-related pathways and HCM(Sarc) showed enhanced proteomic and phosphoproteomic alterations in these pathways. Thus, we show HCM(Sarc) has enhanced proteomic and phosphoproteomic dysregulation observed which may contribute to the more severe disease phenotype.

Item Type: Article
Subjects: R Medicine > R Medicine (General)
Depositing User: Repository Administrator
Date Deposited: 01 May 2024 04:32
Last Modified: 01 May 2024 04:32
URI: http://eprints.victorchang.edu.au/id/eprint/1463

Actions (login required)

View Item View Item